Physician profile
Jachi Sun
NPI 1124175005
$13,052.93
in general payments reported to CMS, 2019-2025
41 companies · $1,760 in 2025
The $1,760 reported for 2025 was more than what 76% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,024 · 2020: $1,776 · 2021: $1,801 · 2022: $1,933 · 2023: $2,439 · 2024: $2,319 · 2025: $1,760.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,380 · Education: $138.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,380.30 |
| Education | $138.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,040.22 | 2019-2025 | Linzess, Mavyret, Viberzi |
| Qol Medical, LLC | $1,305.90 | 2019-2023 | Sucraid |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $890.04 | 2019-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $853.95 | 2019-2025 | Entyvio, Vpriv, Eohilia |
| Celgene Corporation | $784.59 | 2021-2024 | Zeposia |
| Janssen Biotech, INC. | $760.07 | 2019-2025 | Stelara, Simponi Aria, Remicade |
| Gilead Sciences, INC. | $689.35 | 2019-2025 | |
| Intercept Pharmaceuticals, INC. | $434.98 | 2020-2023 | Ocaliva |
| Ardelyx, INC. | $414.31 | 2022-2025 | Ibsrela |
| Pfizer INC. | $382.93 | 2020-2025 | |
| Regeneron Healthcare Solutions, INC. | $359.03 | 2023-2025 | Dupixent |
| Shield Therapeutics INC | $310.57 | 2023-2025 | Accrufer |
| Phathom Pharmaceuticals, INC. | $250.00 | 2024 | Voquezna |
| Boston Scientific Corporation | $201.63 | 2019-2024 | Resolution 360 Clip |
| Ironwood Pharmaceuticals, INC | $199.46 | 2020-2024 | Linzess |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $182.18 | 2020-2021 | |
| Aimmune Therapeutics, INC. | $172.43 | 2024-2025 | Zenpep |
| Redhill Biopharma INC. | $171.81 | 2021-2022 | |
| Nestle Healthcare Nutrition INC. | $154.84 | 2021-2023 | |
| Ethicon US, LLC | $150.46 | 2020-2022 | |
| Romark Laboratories, Lc | $125.10 | 2020 | |
| Evoke Pharma, INC. | $124.51 | 2020-2025 | Gimoti |
| Celltrion USA INC. | $120.00 | 2024-2025 | Vegzelma |
| Genzyme Corporation | $114.15 | 2023-2025 | |
| Lilly USA, LLC | $112.08 | 2024-2025 | Omvoh |
| E.R. Squibb & Sons, L.L.C. | $99.93 | 2021 | |
| Allergan, INC. | $93.83 | 2019-2020 | |
| Medtronic, INC. | $81.02 | 2023-2025 | Gi Genius, Pillcam, Barrx |
| Madrigal Pharmaceuticals | $80.05 | 2024-2025 | Rezdiffra, Resmetirom |
| Echosens North America, INC. | $66.81 | 2025 | Fibroscan |
| Braintree Laboratories, INC. | $50.88 | 2019-2023 | Suflave |
| Fujifilm Healthcare Americas Corporation | $41.12 | 2023 | Fujifilm |
| Exact Sciences Corporation | $35.77 | 2023 | Cologuard Collection Kit |
| Ferring Pharmaceuticals INC. | $35.38 | 2020-2023 | Clenpiq |
| Intra-Sana Laboratories | $28.66 | 2025 | Glycate, Reltone 400 Mg, Reltone 200 Mg |
| Merck Sharp & Dohme LLC | $28.42 | 2024 | Dificid |
| Mallinckrodt Hospital Products INC. | $26.44 | 2025 | Terlivaz |
| Shionogi INC | $23.63 | 2019 | |
| Vivus LLC | $20.84 | 2025 | Pancreaze |
| Biocon Biologics INC | $18.34 | 2024 | Hulio |
| Vibrant Gastro, INC. | $17.22 | 2023 | Vibrant Starter Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jachi Sun listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.